Bringing AI-driven protein-design tools to biologists everywhere
Founded by Tristan Bepler PhD ’20 and former MIT professor Tim Lu PhD ’07, OpenProtein.AI offers researchers open-source models and other tools for protein engineering.
Founded by Tristan Bepler PhD ’20 and former MIT professor Tim Lu PhD ’07, OpenProtein.AI offers researchers open-source models and other tools for protein engineering.
A new study suggests that the chemical NDMA is much more likely to cause cancerous mutations after exposure early in life.
Graduate engineering program is No. 1 in the nation; MIT Sloan is No. 6.
Computational biologist Sergei Kotelnikov is working to develop new methods in protein modeling as part of the School of Science Dean’s Postdoctoral Fellowship.
A backup survival pathway can help tumor cells resist certain lung cancer and other drugs. Combining therapies may offer a solution.
SMART breakthrough offers a promising pathway toward improved manufacturing of high‑quality cells for regenerative therapies to treat joint diseases.
The technology could enable fast, point-of-care diagnoses for pneumonia and other lung conditions.
Faculty members and researchers were honored in recognition of their scholarship, service, and overall excellence.
Offering substantial prize funding alongside workshops, classes, and mentorship, the initiative helps translate early-stage biotech research into venture-ready innovation.
By providing holistic information on a cell, an AI-driven method could help scientists better understand disease mechanisms and plan experiments.
In STS.059 (The Bioeconomy and Society), students explore the social and political factors at work in the biology, biotech, and biological engineering sectors.
Seven faculty members, along with 12 additional alumni, are honored for significant contributions to engineering research, practice, and education.
MIT researchers used a large language model to optimize the genetic sequences of proteins manufactured by yeast, making production more efficient.
Driven by overuse and misuse of antibiotics, drug-resistant infections are on the rise, while development of new antibacterial tools has slowed.
Based on a virus-like particle built with a DNA scaffold, the approach could generate broadly neutralizing antibody responses against HIV or influenza.